SOHO 2024 live congress feed

CONGRESS | #SOHO2024 | Poster
Jorge Cortes, @AUG_University, presents 5-year data from phase II registration trial (NCT02719574) of olutasidenib in a subgroup of pts with AML following venetoclax failure (N=18). In 16 pts with IDH1m AML R/R to venetoclax, CR/CRh rate was 31%,… pic.twitter.com/pH8Pn5fvE3

— AML Hub (@AML_Hub) September 6, 2024

CONGRESS | #SOHO2024 | Poster
Alexander Perl, @Penn, presents potential prognostic utility of FLT3-ITD-specific MRD assessment in pts with AML from the phase III QuANTUM-First trial (n=321 with available MRD data). Reduction in FLT3-ITD MRD was associated with longer OS across… pic.twitter.com/d8SXo2yqei

— AML Hub (@AML_Hub) September 6, 2024

CONGRESS | #SOHO2024 | Poster
Manuel Espinoza-Gutarra, @ONealCancerUAB, presents real-world outcomes of FLT3- or IDH-targeted TKI therapy in pts with AML (N=482). Patients treated at first line vs second line or beyond had similar rwEFS (2.2 vs 2.5 months) and rwOS (12.3 vs 13.1… pic.twitter.com/02skw6cULE

— AML Hub (@AML_Hub) September 6, 2024

CONGRESS | #SOHO2024 | Poster
Samer Srour, @MDAndersonNews, presents subgroup analysis of phase Ib (NCT04013685) trial of Orca-T in patients with AML (N=37). At 12 months, relapse-free survival was 82.5%, non-relapse mortality was 0%, and overall survival was 100%.#AMLsm #leusm… pic.twitter.com/xEYwKl2AZy

— AML Hub (@AML_Hub) September 6, 2024

CONGRESS | #SOHO2024 | Poster
Uma Borate, @OSUCCC_James, presents phase II SELECT-AML-1 (NCT04905407) results of tamibarotene + Ven/Aza in pts with ND unfit AML with RARA overexpression (N=51). CR/CRi rates were 60% with tamibarotene/Ven/Aza vs 69% with Ven/Aza. The combination… pic.twitter.com/m2ngcy2Bh2

— AML Hub (@AML_Hub) September 6, 2024

CONGRESS | #SOHO2024 | Poster
Harry Erba, @DukeCancer, presents a post hoc analysis of QuANTUM-First study assessing the impact of age on efficacy of quizartinib in patients with ND FLT3-ITD+ AML. Among 297 pts achieving CR at the end of induction, CR rates were similar with… pic.twitter.com/tgRWDiOJiv

— AML Hub (@AML_Hub) September 6, 2024

CONGRESS | #SOHO2024 | Poster
Priti Pednekar presents an observational study assessing adherence and persistence to FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML (N=162). Patients with pre-alloHCT R/R AML were more likely to be adherent (41.5% vs 21.4%,… pic.twitter.com/HAypSdQ3IS

— AML Hub (@AML_Hub) September 5, 2024

CONGRESS | #SOHO2024
Charles Craddock, @TQEHofficial, discusses identification of patients with AML over 70 years in CR1 who could benefit from transplant, optimal conditioning regimen, and post-transplant maintenance strategies to minimize the risk of relapse. Suitability for… pic.twitter.com/okGIQRaw5R

— AML Hub (@AML_Hub) September 5, 2024

CONGRESS | #SOHO2024@Eduardomrego, @usponline, discusses the international expansion of modern AML therapies, highlighting the need for better molecular testing and access to novel treatments in low- and middle-income countries. To address these gaps, the ICAML2015 protocol was… pic.twitter.com/h93HMudYnG

— AML Hub (@AML_Hub) September 5, 2024

CONGRESS | #SOHO2024
Jayalekshmi Jayakumar, @official_tbhc, shares findings from a nationwide study evaluating the role of aspirin in improving leukemia outcomes. Out of 1,663,149 leukemia-related hospitalizations, 11.2% were aspirin users, who were older than non-users, and… pic.twitter.com/R4FtTOgV2N

— AML Hub (@AML_Hub) September 5, 2024

CONGRESS | #SOHO2024
Marion Subklewe @subklewe, @LMU_Uniklinikum, discusses current landscape and ongoing trials of immune or cellular therapies in the management of AML, including antibody drug conjugates (ADCs) & fusion proteins, monoclonal antibodies & checkpoint inhibitors, T… pic.twitter.com/BrQk231WvQ

— AML Hub (@AML_Hub) September 5, 2024

CONGRESS | #SOHO2024
Stéphane De Botton, @GustaveRoussy, debates the case that AZA + VEN dose reductions are not detrimental, and that shorter VEN durations, as recommended by the ELN, may allow hematological recovery. He also cites a French study showing no significant… pic.twitter.com/KajskbCMFr

— AML Hub (@AML_Hub) September 5, 2024

CONGRESS | #SOHO2024
Keith Pratz @PratzKW @PennMedicine debates the case that azacytidine plus venetoclax should be prescribed as listed on the label; concluding that the data from the VIALE-A trial is the only randomized data set demonstrating a survival benefit, therefore until… pic.twitter.com/K4VskpUs1z

— AML Hub (@AML_Hub) September 4, 2024

CONGRESS | #SOHO2024@DrChrisHourigan @FralinBiomed discusses MRD as a surrogate endpoint for clinical trials in #AML, emphasizing the difference between the cases for regulatory and clinical use but noting that there is potential for its use as a surrogate in the future. #AMLsm… pic.twitter.com/3Hvtfs1H0K

— AML Hub (@AML_Hub) September 4, 2024

CONGRESS | #SOHO2024
Mark Levis @HopkinsMedicine discusses the unanswered question in FLT3 Mutated AM; emphasizing the importance of sequencing in individualized treatment strategies and the need for further investigation of multiclonal FLT3-ITD.#AMLsm #leusm pic.twitter.com/VxmUujI2Ca

— AML Hub (@AML_Hub) September 4, 2024

CONGRESS | #SOHO2024
Keith Pratz @PratzKW @PennMedicine debates the case that azacytidine plus venetoclax should be prescribed as listed on the label; concluding that the data from the VIALE-A trial is the only randomized data set demonstrating a survival benefit, therefore until… pic.twitter.com/K4VskpUs1z

— AML Hub (@AML_Hub) September 4, 2024